Derivative Suit Against Cephalon Board, CEO Tossed
A federal judge has dismissed a shareholder derivative suit against biopharmaceutical company Cephalon Inc.'s board and CEO, accusing them of failing to properly oversee the company's sales and promotions practices with...To view the full article, register now.
Already a subscriber? Click here to view full article